 |
53 Diseases |  |
490 Trials |
|
490 Trials |  |
8927 News |  |
| «12...2122232425262728293031...123124» |
- | Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Journal, PD(L)-1 Biomarker: Pretreatment eosinophil count predicts response to atezolizumab plus bevacizumab therapy in patients with hepatocellular carcinoma. (Pubmed Central) - Dec 12, 2023
A high pretreatment eosinophil count predicted a better response to ATZ/BEV therapy for u-HCC and was associated with the incidence of AEs (? grade 3).
- ||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Metastases: LEAP-001 China Extension: Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) - China Extension Study (clinicaltrials.gov) - Dec 10, 2023
P3, N=875, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
grade 3). Trial completion date: Apr 2024 --> Apr 2025
- || Review, Journal: An Overview of the Use of Anti-Angiogenic Agents in the Treatment of Thymic Epithelial Tumors. (Pubmed Central) - Dec 9, 2023
The current evidence suggests that the most active agent is lenvatinib, whereas sunitinib could be proposed as an acceptable second-line therapy for TC. Further research concerning the combination of immune checkpoint inhibitors with anti-angiogenic drugs is warranted.
- | Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Journal, Real-world evidence, Real-world: Real-World Systemic Treatment Patterns after Atezolizumab and Bevacizumab in Patients with Hepatocellular Carcinoma in the United States. (Pubmed Central) - Dec 9, 2023
The median time from index to next treatment post-atezo + bev was 5.4 months. Further research is needed to identify the patients who are most likely to benefit from atezo + bev as well as later-line HCC therapies to optimize overall survival.
- | erlotinib / Generic mfg.
New P1 trial: Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors (clinicaltrials.gov) - Dec 8, 2023
P1, N=70, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Retrospective data, Review, Journal, Real-world evidence, Real-world: Efficacy and safety comparison between Lenvatinib and Sorafenib in hepatocellular carcinoma treatment: a systematic review and meta-analysis of real-world study. (Pubmed Central) - Dec 7, 2023
We found that treatment with Lenvatinib in HCC patients resulted in better OS, PFS, and higher ORR and DCR compared to Sorafenib. However, safety data indicated that Lenvatinib did not exhibit a significant advantage.
- Stivarga (regorafenib) / Bayer, Tecentriq (atezolizumab) / Roche, zanzalintinib (XL092) / Exelixis
Zanzalintinib (XL092) plus atezolizumab versus regorafenib in previously treated MSS/MSI-low metastatic colorectal cancer (mCRC): The randomized phase 3 STELLAR-303 study. (Level 1, West Hall; Poster Bd # N17) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_642;
P3
However, safety data indicated that Lenvatinib did not exhibit a significant advantage. Most recently, in the phase 3 LEAP-017 study of patients with non
- Imfinzi (durvalumab) / AstraZeneca, Lenvima (lenvatinib) / Eisai, Merck (MSD)
The interim analysis of a single-arm, open-label, phase II study investigating ALLEN regimen (durvalumab plus albumin paclitaxel and lenvatinib) in patients with metastatic pancreatic cancer (mPC). (Poster Bd # L7) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_573;
P1/2
Further randomized controlled studies will be required in a larger patient population. Clinical trial information: NCT05327582.
- E7386 / Eisai, PRISM Pharma, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Analysis of tumor biomarkers in patients (pts) with advanced hepatocellular carcinoma (HCC) from a phase 1b study of E7386, a CREB-binding protein/?-catenin interaction inhibitor, in combination with lenvatinib. (Poster Bd # F2) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_474;
P1
This concept is the basis for treatment with this combination. However, given the small sample size, further investigation is needed to confirm these effects on the tumor microenvironment.
- Stivarga (regorafenib) / Bayer
Cost-utility analysis of sequential therapy with sorafenib followed by regorafenib versus single-line therapies in advanced hepatocellular carcinoma. (Poster Bd # E16) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_468;
We evaluated the lifetime cost-effectiveness of a sequence of treatment with sorafenib followed by regorafenib (SOR-REG) compared with licensed single-line therapies for which there is no clear sequencing options available, including atezolizumab plus bevacizumab (ATEZO+BEV), which has become the standard of care in first-line treatment, as well as lenvatinib (LEN), followed by best supportive care (BSC). A sequence of SOR-REG for patients with advanced HCC is cost-effective at WTP thresholds of
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Novel GPC3-targeting radiopharmaceutical therapy for hepatocellular carcinoma. (Poster Bd # E12) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_464;
A sequence of SOR-REG for patients with advanced HCC is cost-effective at WTP thresholds of Preclinical in vitro and in vivo data demonstrate the potential of RAYZ-8009 as a theranostic agent for the treatment of patients with GPC3+ HCC.
- Tevimbra (tislelizumab) / BeiGene, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Neo-adjuvant tislelizumab combined with lenvatinib treatment for resectable, recurrent hepatocellular carcinoma. (Poster Bd # E4) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_458;
P2
The long-term results of this combined treatment approach are eagerly anticipated. Clinical trial information: NCT04615143.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Adjuvant TACE plus lenvatinib as compared with TACE alone in patients with hepatocellular carcinoma at high risk of recurrence after surgery: A prospective controlled study. (Poster Bd # D12) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_447;
The toxicity of combined treatment was tolerable and manageable. The follow up is still ongoing to observe the long-term benefit of this treatment regimen.
- Imfinzi (durvalumab) / AstraZeneca, Lenvima (lenvatinib) / Eisai, Merck (MSD)
The interim analysis of a single-arm, open-label, phase II study investigating ALLEN regimen (durvalumab plus albumin paclitaxel and lenvatinib) in patients with unresectable biliary tract cancers (BTCs). (Poster Bd # D11) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_446;
P1/2
The preliminary results were promising, which deserved further investigation in a larger population. Clinical trial information: NCT05327582.
- Tevimbra (tislelizumab) / BeiGene, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Perioperative lenvatinib combined with tislelizumab plus transcatheter arterial chemoembolization in resectable hepatocellular carcinoma with high-risk of recurrence: A prospective, single-arm, phase 2 trial. (Poster Bd # D10) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_445;
Lenvatinib, tislelizumab, and TACE were safe and showed promising efficacy as a neoadjuvant therapy for resectable HCC with high risk of recurrence. Clinical trial information: ChiCTR2100048249.
- Tevimbra (tislelizumab) / BeiGene, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and tislelizumab for unresectable hepatocellular carcinoma: A single-arm, phase II study. (Poster Bd # D7) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_443;
The study is ongoing, OS will be reported later. Clinical trial information: ChiCTR2200064384.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Lenvatinib plus hepatic arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma. (Poster Bd # D3) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_440;
Lenva+CDDP demonstrated a better response and patient outcome than lenvatinib, and was well-tolerated in patients with advanced HCC. We are currently conducting a randomized controlled trial comparing the efficacy of these treatments.
- Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Phase II study of atezolizumab and bevacizumab combination therapy for patients with advanced hepatocellular carcinoma who previously received systemic treatment. (Poster Bd # D2) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_439;
It may therefore be a treatment option for patients with advanced HCC previously treated with lenvatinib. Clinical trial information: jRCT1041200068.
- Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
Comparison of the treatment effect between lenvatinib and atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in pathologically diagnosed metabolic dysfunction (Poster Bd # C18) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_437;
Outcomes of LEN and ATZ/Bev treatment for advanced HCC were not different in pathologically confirmed MASLD. Longer OS of LEN than ATZ/Bev was observed in the patients with relatively better liver function, suggesting that LEN might be a suitable first-line treatment for HCC with compensated liver function in the patients with pathologically confirmed MASLD.
- Understanding the efficacy of frontline therapies for hepatocellular carcinoma through etiologic stratification. (Poster Bd # C16) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_435;
However, small population sizes and potential nonrandom covariate missingness in this study may obscure effects. Future studies are needed to further elucidate this trend along with subpopulation effects of other systemic therapies.
- Tevimbra (tislelizumab) / BeiGene, Lenvima (lenvatinib) / Eisai, Merck (MSD)
A single-arm, multi-center phase II study of tislelizumab combined with lenvatinib and GEMOX as conversion therapy in potentially resectable locally advanced biliary tract cancer (ZSAB-TransGOLP): A primary analysis. (Poster Bd # C13) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_432;
P2
Survival data will continue to be followed up. Clinical trial information: NCT05156788.
- quavonlimab/pembrolizumab (MK-1308A) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Coformulated quavonlimab and pembrolizumab (pembro) in combination with lenvatinib (lenva) as first-line (1L) therapy for patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 2 KEYSTEP-004 study. (Poster Bd # C9) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_428;
P2
The coformulation of quavonlimab and pembrolizumab in combination with lenvatinib demonstrated manageable safety; further investigation is warranted to understand the efficacy of this triplet as 1L treatment for advanced HCC. Clinical trial information: NCT04740307.
- Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Lenvatinib plus pembrolizumab versus lenvatinib alone as first-line therapy for advanced hepatocellular carcinoma: Longer-term efficacy and safety results from the phase 3 LEAP-002 study. (Poster Bd # C7) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_426;
P3
The median OS of 19.0 mo with len monotherapy continues to support its role as a standard-of-care treatment in 1L advanced HCC. The activity of len + pembro for pts with advanced HCC observed in this study supports the evaluation of TACE
- Kaitanni (cadonilimab) / Akesobio, Lenvima (lenvatinib) / Eisai, Merck (MSD)
The efficacy and safety of transarterial chemoembolization combined with cadonilimab and lenvatinib for unresectable hepatocellular carcinoma: A phase II clinical trial. (Poster Bd # C3) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_422;
P2
Benefit of control on tumor progression after TACE and lasting survival can be expected. Clinical trial information: NCT05319431.
- fostroxacitabine bralpamide (MIV-818) / Medivir, Lenvima (lenvatinib) / Eisai, Merck (MSD)
First safety and efficacy data from phase Ib/IIa study of fostroxacitabine bralpamide (fostrox, MIV-818) in combination with lenvatinib in patients with hepatocellular carcinoma (HCC). (Poster Bd # C1) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_420;
P1/2
Fostrox in combination with lenvatinib, in pts with HCC who progressed on previous systemic treatment, had an acceptable safety and tolerability profile with promising interim efficacy results from the completely enrolled phase Ib/IIa study. Clinical trial information: NCT03781934.
- Promising first-line immuno-combination therapies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis. (Poster Bd # B14) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_413;
A Markov model was built based on five global, multicenter, open-label, phase III randomized trials (Himalaya, IMbrave150, ORIENT-32, CARES-310, LEAP-002) to investigate the cost-effectiveness of tremelimumab plus durvalumab (STRIDE), atezolizumab plus bevacizumab (A+B), sintilimab plus bevacizumab biosimilar (IBI305) (S+B), camrelizumab plus rivoceranib (C+R) and pembrolizumab plus lenvatinib (P+L). As one of the promising immuno-combination therapies in the first-line systemic treatment for unresectable HCC, camrelizumab plus rivoceranib demonstrated the potential to be the most cost-effective strategy, which warranted further studies to best inform the real-world clinical practices.
- Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
Organ-specific response with first-line atezolizumab-bevacizumab versus lenvatinib for patients with advanced hepatocellular carcinoma. (Poster Bd # B12) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_411;
Compared to lenvatinib, atezolizumab-bevacizumab was associated with a favorable organ-specific response regardless of the site of the tumor lesions. Unlike anti-PD-1 monotherapy, atezolizumab-bevacizumab had a comparable organ-specific response between intrahepatic and extrahepatic lesions, especially for those with viral etiology HCCs.
- Characterization of outcomes and genomic alterations (GA) in combined hepatocellular carcinoma-cholangiocarcinoma (cHCC-CCA). (Poster Bd # B3) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_402;
Pts who present with early stage of disease should be evaluated early for surgical resection or maximize local therapy in the case of nonresectable disease to improve survival. >
- Opdivo (nivolumab) / Ono Pharma, BMS, Lenvima (lenvatinib) / Eisai, Merck (MSD)
First-line therapies in a Latino-rich cohort of US patients (pts) with hepatocellular carcinoma (HCC) and Child Pugh B (CPB) cirrhosis. (Poster Bd # A18) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_397;
Further investigation of survival based on ALBI levels and the trajectory of liver function over time in response to different treatment approaches is underway in a larger cohort who has received newer immunotherapy-based regimens. With more agents approved for HCC, prospective clinical trials are needed in CPB and HCC.
- Opdivo (nivolumab) / Ono Pharma, BMS, Stivarga (regorafenib) / Bayer, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Real-world survival outcomes and treatment patterns in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Results from the OREIOS study. (Poster Bd # A14) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_393;
P=N/A
With novel agents and combination therapies being approved for uHCC, integrating them in routine care is important to improve survival. Alongside, further real-world studies are warranted for evaluating the change in treatment patterns and prognosis.
- Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Racial/ethnic disparities in the effectiveness of atezolizumab plus bevacizumab (A+B) vs. tyrosine kinase inhibitors (TKIs) among veterans with unresectable hepatocellular carcinoma (uHCC). (Poster Bd # A13) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_392;
Understanding the factors contributing to the effectiveness of A+B across racial/ethnic groups could provide valuable insights for guiding future trials and initiatives aimed at addressing racial disparities in HCC. >* p < 0.05.
- Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
Comparing first-line (1L) atezolizumab plus bevacizumab (A+B) to lenvatinib (L) or sorafenib (S) in patients with unresectable hepatocellular carcinoma (uHCC): Findings from the National Veteran Health Administration (VHA) database. (Poster Bd # A11) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_390;
In a real-world VHA experience with A+B among diverse patient groups, a clinically notable survival benefit was observed with A+B compared to L or S. Future evaluations of the safety of using A+B in patients with greater liver dysfunction, including CP B and cirrhosis, are needed to evaluate the expanded use of A+B. >
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Lenvatinib in recurrent hepatocellular carcinoma after liver transplantation. (Poster Bd # P7) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_356;
P2
This study is currently enrolling patients. Clinical trial information: NCT05103904.
- Keytruda (pembrolizumab) / Merck (MSD), Welireg (belzutifan) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Phase 2 study of pembrolizumab plus lenvatinib and belzutifan in patients with metastatic esophageal squamous cell carcinoma. (Poster Bd # N10) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_128;
P2
Enrollment for this study began in September 2022 and is ongoing across 48 global sites. Clinical trial information: NCT04976634.
- | Tevimbra (tislelizumab-jsgr) / BeiGene, Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial, Metastases: Lenvatinib Plus Tislelizumab and CapeOX as First-Line Treatment for Advanced GC/GEJC With Positive PD-L1 and Low TMEscore (clinicaltrials.gov) - Dec 6, 2023
P2, N=92, Recruiting, Sponsor: Nanfang Hospital, Southern Medical University
- | Tevimbra (tislelizumab-jsgr) / BeiGene, Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P4 trial: High-dose irradiation plus low-dose radiatlion combined with tislelizumab and lenvatinib for unresectable hepatocellular carcinoma: a single-arm, phase II study (EUDRACT) - Dec 5, 2023
P4, N=56, Recruiting, Sponsor: Pingxiang People's Hospital; Pingxiang People's Hospital
Clinical trial information: NCT04976634. .
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P4 trial: Camrelizumab combined with TACE and targeted therapy VS TACE combined with targeted therapy for primary hepatocellular carcinoma with portal vein tumor thrombus: a comparative study (EUDRACT) - Dec 5, 2023
P4, N=78, Not yet recruiting, Sponsor: The First Affiliated Hospital, Zhejiang University School of Medicine; The First Affiliated Hospital, Zhejiang University School of Medicine
. .
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P3 trial: Clinical study of lenvatinib in the treatment of intermediate stage liver cancer after failure of transcatheter arterial chemoembolization (EUDRACT) - Dec 5, 2023
P3, N=66, Not yet recruiting, Sponsor: Beijing Ditan Hospital, Capital Medical University; Beijing Ditan Hospital, Capital Medical University
. .
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2/3 trial, Surgery: The efficacy and safety of envolizumab combined with lenvatinib and capecitabine for biliary tract cancers with high-risk recurrence after surgery (EUDRACT) - Dec 5, 2023
P2/3, N=30, Not yet recruiting, Sponsor: Sir Run-Run Shaw Hospital, Zhejiang University; Sir Run-Run Shaw Hospital, Zhejiang University
. .
- | Tevimbra (tislelizumab-jsgr) / BeiGene, Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial: A prospective, open, multicenter, cohort study of neoadjuvant therapy with TACE, lenvatinib and tislelizumab versus surgical resection alone for stage A BCLC patients with single HCC larger than 5cm in diameter (EUDRACT) - Dec 5, 2023
P2, N=120, Recruiting, Sponsor: Fujian Provincial Hospital; Fujian Provincial Hospital
. .
- | Tyvyt (sintilimab) / Eli Lilly, Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial: A singel-arm, exploratory clinical study of SBRT sequential TACE combined with lenvatinib and sintilimab in the treatment of unresectable HCC with type III PVTT (EUDRACT) - Dec 5, 2023
P2, N=70, Not yet recruiting, Sponsor: Fujian Provincial Hospital; Fujian Provincial Hospital
. .
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal, Metastases: A prospective study exploring the safety and efficacy of lenvatinib for patients with advanced hepatocellular carcinoma and high tumor burden: The LAUNCH study. (Pubmed Central) - Dec 4, 2023
Lenvatinib is safe and effective for advanced HCC in patients with Child-Pugh A, even with high tumor burden. However, it carries a higher risk of AEs and may not provide adequate efficacy for patients with Child-Pugh B.
- | HC-5404 / HiberCell
Preclinical, Journal: PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors. (Pubmed Central) - Dec 4, 2023
However, it carries a higher risk of AEs and may not provide adequate efficacy for patients with Child-Pugh B. By disrupting an adaptive stress response evoked by VEGFR-TKIs, HC-5404 presents a clinical opportunity to improve the antitumor effects of well-established standard of care therapies in RCC.
- | E7386 / Eisai, PRISM Pharma
Phase classification: KEYNOTE-C83: A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors (clinicaltrials.gov) - Dec 4, 2023
P1/2, N=156, Recruiting, Sponsor: Eisai Inc.
By disrupting an adaptive stress response evoked by VEGFR-TKIs, HC-5404 presents a clinical opportunity to improve the antitumor effects of well-established standard of care therapies in RCC. Phase classification: P1b/2 --> P1/2
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Preclinical, Journal: Lenvatinib-Loaded Poly(lactic-co-glycolic acid) Nanoparticles with Epidermal Growth Factor Receptor Antibody Conjugation as a Preclinical Approach to Therapeutically Improve Thyroid Cancer with Aggressive Behavior. (Pubmed Central) - Nov 29, 2023
Phase classification: P1b/2 --> P1/2 These proof-of-concept findings suggest a promising strategy for administering TKIs in a more targeted and effective manner.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Preclinical, Journal: Increased c?SRC expression is involved in acquired resistance to lenvatinib in hepatocellular carcinoma. (Pubmed Central) - Nov 29, 2023
When co-administering dasatinib, a c-SRC inhibitor, the partial restoration of lenvatinib sensitivity in the JHH-7_LR cell line was observed. The present study demonstrated that increased c-SRC expression was partially associated with HCC resistance to lenvatinib, suggesting that c-SRC inhibition could reduce the resistance of HCC to lenvatinib.
- | Journal: Aneurysm and Artery Dissection After Oral VEGFR-TKI Use in Adults With Cancer. (Pubmed Central) - Nov 29, 2023
In this study, the use of oral VEGFR-TKIs was associated with an increased risk of AAD occurrence. These findings elucidate vascular toxic effects and may provide a substantial reference for reducing the socioeconomic burden of adverse events associated with VEGFR-TKI use.
- | Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci
Trial completion date, Trial termination, Trial primary completion date, Combination therapy: Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma (clinicaltrials.gov) - Nov 29, 2023
P1/2, N=40, Terminated, Sponsor: Shanghai Junshi Bioscience Co., Ltd.
These findings elucidate vascular toxic effects and may provide a substantial reference for reducing the socioeconomic burden of adverse events associated with VEGFR-TKI use. Trial completion date: Oct 2022 --> Aug 2023 | Recruiting --> Terminated | Trial primary completion date: Jul 2022 --> Aug 2023; Enrollment is over, the study was completed
- | Trial initiation date: OPTI-DOSE: OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults (clinicaltrials.gov) - Nov 29, 2023
P4, N=30, Not yet recruiting, Sponsor: University Medical Center Groningen
Trial completion date: Oct 2022 --> Aug 2023 | Recruiting --> Terminated | Trial primary completion date: Jul 2022 --> Aug 2023; Enrollment is over, the study was completed Initiation date: Sep 2023 --> May 2024
- || Keytruda (pembrolizumab) / Merck (MSD), Lysodren (mitotane) / Perrigo Company, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open, Metastases: ACCOMPLISH: Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical Carcinoma (clinicaltrials.gov) - Nov 29, 2023
P2, N=30, Enrolling by invitation, Sponsor: National Cancer Center, Korea
Initiation date: Sep 2023 --> May 2024 Not yet recruiting --> Enrolling by invitation